Cargando…

Phase II Study of Adjuvant Chemoradiotherapy Using Docetaxel/Cisplatin/5-Fluorouracil Before and After Intensity-modulated Radiotherapy With Concurrent Docetaxel in Patients With Completely (R0) Resected Gastric Carcinoma

OBJECTIVES: The Intergroup 0116 study has demonstrated a significant survival benefit for completely resected (R0) gastric cancer patients treated with a fluorouracil/leucovorin chemoradiotherapy regimen. However, this regimen is also toxic and less effective in terms of distant disease control. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yong, Zhao, Guoqi, Xu, Yi, Zhang, Tiening, Chen, Zhixiao, Yan, Ge, Tu, Wenzhi, Hu, Ye, Chen, Ying, He, Xia, Li, Xiaodong, Chen, Hui, Yao, Shengyu, Hu, Zhekai, Chen, Xuming, Chen, Tingfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Original Articles: Gastrointestinal
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023597/ https://www.ncbi.nlm.nih.gov/pubmed/28263232 http://dx.doi.org/10.1097/COC.0000000000000373

Ejemplares similares

Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-fluorouracil Improves Survival of Patients with Advanced Esophageal Cancer Compared with Conventional Concurrent Chemoradiotherapy with Cisplatin and 5-fluorouracil
por: Tamaki, Yukihisa, et al.
Publicado: (2018)

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
por: Zeng, Zhen, et al.
Publicado: (2018)

Concurrent chemoradiotherapy with intravenous cisplatin and docetaxel for advanced oral cancer
por: Sato, Kotaro, et al.
Publicado: (2019)

Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma
por: Chen, Ruijuan, et al.
Publicado: (2021)

Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report
por: Watanabe, Sho, et al.
Publicado: (2019)

Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
por: Zhou, Xi-Lei, et al.
Publicado: (2021)

Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial
por: Wang, Yan, et al.
Publicado: (2022)

Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma
por: Fangzheng, Wang, et al.
Publicado: (2017)

A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin versus 5-Fluorouracil plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma
por: Zhu, Yujia, et al.
Publicado: (2017)

Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis
por: Zhang, Peng, et al.
Publicado: (2016)

Adjuvant Chemotherapy with Docetaxel, Cisplatin, and Continuous-Infusion 5-Fluorouracil for Gastric Cancer: A Phase II Study()
por: Meng, Changting, et al.
Publicado: (2014)

Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial
por: Jiang, Hui, et al.
Publicado: (2023)

Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer
por: Fu, Jin Ye, et al.
Publicado: (2022)

Definitive Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil for Advanced Cervical Esophageal Cancer: A Medium-Term Outcome
por: Okamoto, Hiroshi, et al.
Publicado: (2022)

Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
por: Katori, H, et al.
Publicado: (2004)

Complete remission in very advanced oral cancer by docetaxel, cisplatin, 5-fluorouracil based induction chemotherapy followed by concurrent chemoradiation
por: Chiang, Tien-En, et al.
Publicado: (2018)

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma()()()()
por: Jin, Ting, et al.
Publicado: (2019)

Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer
por: Katayama, H, et al.
Publicado: (2004)

Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis
por: Li, Bo, et al.
Publicado: (2019)

Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study
por: Burtness, Barbara, et al.
Publicado: (2016)

Randomized Phase II Study to Comparing Docetaxel/Nedaplatin versus Docetaxel for 5-Fluorouracil/Cisplatin Resistant Esophageal Squamous Cell Carcinoma
por: Yajima, Satoshi, et al.
Publicado: (2021)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020)

Long term complications and prognostic factors in locally advanced nasopharyngeal carcinoma treated with docetaxel, cisplatin, 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy: A retrospective cohort study
por: Shim, Hyun Jeong, et al.
Publicado: (2020)

Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis
por: Liao, Jun-Fang, et al.
Publicado: (2019)

Clinical value of docetaxel plus cisplatin (TP) induction chemotherapy followed by TP concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma
por: Tao, Hao-Yun, et al.
Publicado: (2021)

Dosimetric Comparison Between Jaw Tracking and No Jaw Tracking in Intensity-Modulated Radiation Therapy
por: Yao, Shengyu, et al.
Publicado: (2019)

A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence
por: Liu, Qi, et al.
Publicado: (2020)

Docetaxel, Cisplatin and Fluorouracil (DCF) Regimen Compared with Non-Taxane-Containing Palliative Chemotherapy for Gastric Carcinoma: A Systematic Review and Meta-Analysis
por: Chen, Xiao-Long, et al.
Publicado: (2013)

Advanced Maxillary Sinus Cancer Treated with Concurrent Chemoradiotherapy with Intra-Arterial Cisplatin/Docetaxel and Oral S-1: Own Experience and Literature Review
por: Nakashima, Torahiko, et al.
Publicado: (2011)

Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer
por: Saitoh, Jun-ichi, et al.
Publicado: (2017)

Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non‐small cell lung cancer: Analysis of dose‐volume parameters
por: Katsui, Kuniaki, et al.
Publicado: (2020)

Correction to: Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis
por: Liao, Jun-Fang, et al.
Publicado: (2019)

Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis
por: Kano, Masayuki, et al.
Publicado: (2019)

Docetaxel, Cisplatin, and 5‐Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma
por: Fiteni, Frédéric, et al.
Publicado: (2016)

Addition of 5-fluorouracil to docetaxel/cisplatin does not improve survival in locoregionally advanced nasopharyngeal carcinoma
por: Fangzheng, Wang, et al.
Publicado: (2017)

Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis
por: Yamaguchi, Takahisa, et al.
Publicado: (2023)

Primary cardiac angiosarcoma: a prolonged response to surgical resection followed by concurrent chemoradiotherapy with docetaxel
por: Jang, Youngwoo, et al.
Publicado: (2016)

Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Yang, Jiangping, et al.
Publicado: (2020)

Preliminary Study of Chemoradiotherapy Using Modified Docetaxel, Cis-diaminodichloroplatinum, and 5-Fluorouracil for Sinonasal Squamous Cell Carcinoma
por: Katagiri, Katsunori, et al.
Publicado: (2021)

Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer
por: Chiarion-Sileni, V, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_rdfcsdvl3to4nq9568fhaup8rl